Headline: Adaptive Biotechnologies (ADPT) Boosts Public Offering to $300M, Prices Shares at $24.11

Adaptive Biotechnologies (ADPT) announced on June 17, 2026, an increase in its public offering, now totaling $300 million. Shares are priced at $24.11 each, marking a significant capital raise for the company. J.P. Morgan, Goldman Sachs & Co. LLC, and Morgan Stanley are serving as lead book-running managers for the offering. Cowen and SVB Securities are acting as co-managers for the transaction. Proceeds from the offering are designated for general corporate purposes, including working capital, operating expenses, and capital expenditures, according to the company.